Immune-Related Adverse Events (irAEs) — explained simply

Immune-related adverse events, or irAEs, are side effects that occur when checkpoint inhibitor immunotherapy loosens the immune system's normal restraints so it can fight cancer more effectively — and that same loosened control occasionally lets immune cells attack healthy tissue too. They are not an infection, an allergy, or a sign that something has "gone wrong" with treatment; they are a recognised, monitored part of how this class of medicine works.

irAEs can be mild and pass with monitoring, or serious enough to need hospital care, and they are graded and managed using NCCN and ASCO immune-related adverse event guidelines. This page explains the concept itself — what makes an irAE different from an ordinary side effect, why it can involve any organ, and why it sometimes shows up later than you'd expect — so that every other symptom-specific page on this site makes more sense.

If you are trying to decide right now whether a specific symptom needs urgent attention, use the checklist below first, then come back to understand the bigger picture.

This table is a starting guide, not a diagnosis. Any symptom that concerns you or a caregiver is worth reporting to your care team rather than assuming it is ordinary.

Timing follows patterns described in NCCN and ASCO immune-related adverse event guidelines. Only a doctor examining you can confirm what a specific symptom means.

Checkpoint inhibitors work by releasing checkpoints — proteins such as PD-1, PD-L1, and CTLA-4 — that normally stop immune cells from overreacting anywhere in the body, not just near a tumour. Because these brakes are removed everywhere at once, occasional overactivity can appear in any organ, which is why irAEs are reported in the skin, gut, liver, lungs, endocrine glands, joints, kidneys, and heart.

This is different from a drug designed to reach one organ or one type of tissue. A checkpoint inhibitor's effect is systemic — it works throughout the immune system, not on one target site. While most patients experience no irAE at all, or only a mild one in a single organ, this mechanism is exactly why oncology teams keep a broad set of blood tests and symptom checks in place throughout treatment, rather than watching just one organ.

Checkpoint inhibitors change how immune cells behave for weeks to months after the last dose, not just while the drug is in the bloodstream. This is why some irAEs — especially endocrine ones like thyroid or pituitary problems — can appear late, sometimes after treatment ends, and a few, once triggered, may need lifelong management rather than resolving completely.

Most irAEs settle once treated, but a minority — particularly endocrine irAEs affecting the thyroid, pituitary, or adrenal glands — can cause a permanent hormone deficiency that needs ongoing replacement medication rather than a one-time treatment course. According to NCCN and ASCO immune-related adverse event guidelines, exactly how long the risk of a new irAE persists after stopping checkpoint inhibitor immunotherapy is still an active area of research, and long-term data beyond a few years remains limited.

Because of this, patients who have received checkpoint inhibitor immunotherapy are generally advised to stay alert to new symptoms and report them promptly, even well after their last dose — this is not a reason for alarm, but a reason to keep the line to your care team open.

• Are Immunotherapy Side Effects Milder Than Chemotherapy? — the paradox explained: usually gentler day to day, occasionally far more serious when an irAE develops.
• No Side Effects at All — Is the Treatment Working? — why having no irAE doesn't mean immunotherapy isn't working.
• Fatigue on Immunotherapy: When It Is Ordinary and When It Is Not — a closer look at the single most common symptom patients report.
• Immunotherapy at CION Cancer Clinics — the full picture of how CION supports patients through immunotherapy and its side effects.

This page is for general information and does not replace a consultation. If you develop severe or persistent symptoms during immunotherapy, call now or go to the nearest emergency department.

Thousands have navigated immunotherapy side effects with us

Most irAEs are manageable when caught early and explained clearly. Take the first step today — our team walks this part of the journey with you.